Humans have consumed psychedelics for at least the last 10,000 years. The outlawing of psychedelics in most of the world in the 20th century didn’t stop that, but it did put an end to promising research into their psychotherapeutic applications to treat depression, addiction, PTSD, anxiety, and trauma. Today, we’re in the midst of a psychedelic renaissance, with some psychedelics fast on their way to becoming legal medicines. One of the key players behind this movement is Rick Doblin, Ph.D.. In 01986, he founded the Multidisciplinary Association of Psychedelic Studies (MAPS), a non-profit research and educational organization that has developed the medical and legal framework for the use of psychedelics to treat mental health conditions. MAPS has distributed over $20 million to fund psychedelic research and education, and in 02017 won fast-tracked “Breakthrough Therapy” designation from the FDA for using MDMA-assisted psychotherapy to treat Post-traumatic stress disorder (PTSD). With legalization now in sight, what is the future of psychedelic medicine? Rick Doblin, Ph.D., is the founder and executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS). He received his doctorate in Public Policy from Harvard’s Kennedy School of Government. His life’s work is to develop legal contexts for the beneficial uses of psychedelics.